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Erythropoietin, the red blood cell-making cytokine, is also a potential cytoprotective agent in heart disease. In
this issue of Cell Stem Cell, Hoch et al. (2011) use two heart failure models, including chemotherapeutic
cardiotoxicity, to reveal a mechanistic connection between reduced cardiomyocyte production of erythro-
poietin and neoangiogenesis by cardiac progenitors.Heart failure—defective performance of
cardiac muscle as a biomechanical
pump—is the final common pathway in
diverse forms of heart disease, e.g., those
resulting from acute ischemic injury,
chronic workload, human mutations, or
adverse effects of certain drugs. Organ-
level performance in these settings is
compromised to varying degrees by
defects in myocytes’ mechanical func-
tion, accumulation of extracellular matrix,
and, typically, an imbalance between
cardiac muscle cell death and the scant
capacity of adult mammalian hearts to
execute effective regenerative growth.
Hence, cardiac muscle cell number is an
especially well-posed target for studies
in regenerative medicine, ranging from
empirical trials of cell grafting, to decod-
ing the genetic networks for cardiac
muscle cell creation and survival, to inves-
tigating dormant progenitor cells in adult
hearts as a novel route to self-repair (Mer-
cola et al., 2011). In this issue of Cell Stem
Cell, Hoch et al. (2011) demonstrate
defects in the Sca-1+ cardiac progenitor
cell (CPC) population (Oh et al., 2003) in
two heart failure-prone models: mice with
a cardiomyocyte-specific deletion of the
transcription factorSTAT3,andmicegiven
doxorubicin, an anti-cancer drugwith pro-
nounced cardiotoxicity. They show that
under heart failure conditions, CPCs are
impaired in generating the new blood
vessels that are essential to assist oxygen
delivery and ensure organ homeostasis.
The authors relate this defect to a dimin-
ished activation of the CCL2/CCR2 che-
mokine pathway, which is reduced in
response to defective production of eryth-
ropoietin (EPO) in failing hearts.
Freshly isolated Sca-1+ cardiac cells
lacked the features of hematopoieticstem cells, endothelial progenitor cells,
or differentiated endothelium, but in cell
culture acquired a vascular endothelial
phenotype, demonstrated by marker
proteins and transcripts, activation of
a VE-Cadherin-Cre lineage marker, and
formation of a branching vascular web. A
similar pattern of phenotypic and func-
tional results was obtained using cloned
Sca-1+ cells from cardiac tissue, obvi-
ating the concern that the apparent
progenitor function of these cells might
have been inferred from a selectively
expanding subpopulation of contami-
nating endothelium, rather than a true
lineage decision by the cells. Endothelial
differentiation was enriched in Sca-1+
cells expressing both the CCL2 receptor
(CCR2) and EPO receptor (EPOR), was
reduced by a CCR2 blocker, and was
suppressed in CPCs fromCCR2-deficient
mice. Similar defects were identified in
CPCs from mice with a cardiomyocyte-
restricted deletion of STAT3, which
affected the CPCs in three further ways:
impaired expression of CCL2, upregula-
tion of the metalloproteinase MMP-12,
and generation of an inhibitory CCL2
cleavage fragment. Conversely, cardiac
Sca-1+ cells’ differentiation into endothe-
lium was rescued when CCL2 was
provided along with an MMP-12 inhibitor.
What drives CCL2 expression in Sca-1+
CPCs? Coexpression of EPOR and CCR2
demarcated the cells that yielded endothe-
lium with the greatest efficiency, suggest-
ing that cardiomyocytes’ expression of
EPO was responsible (Hoch et al., 2011).
Best known as a hematopoietic cytokine
produced by the kidney to drive red blood
cell production in bone marrow—and
used to treat diverse anemias—EPO also
acts as a cytoprotective and angiogenicCell Stem Cecytokine on other diverse cell targets (Leist
et al., 2004). EPO levels in the heart were
suppressed by deleting STAT3 in cardio-
myocytes, with analogous effects pro-
duced in cultured cardiomyocytes by
STAT3 shRNA (Hoch et al., 2011). Con-
versely, treating the conditional STAT3
knockout mice with a long-acting EPO
derivative (CERA: Continuous Erythropoi-
esis Receptor Activator, methoxy polyeth-
ylene glycol-epoetin beta) suppressed
MMP-12 in cardiac Sca-1+ cells, rescued
CCL2, suppressed the progressive loss of
capillary density, and preserved cardiac
pump function. In cultured CPCs from
STAT3 conditional-knockout mice, EPO
enhanced CCL2 expression, endothelial
differentiation, and sprouting. By contrast,
CERA and EPO had no effect on the hearts
or CPCs of wild-type mice. Most features
of this pathway were also evoked by
cardiotoxic levels of the anticancer drug
doxorubicin: lossofSTAT3andEPO incar-
diomyocytes, reduced CCL2 in CPCs,
impaired endothelial differentiation and
capillary density, lethal heart failure, and
a high degree of protection by CERA
(Hochet al., 2011). This intriguingparacrine
and pathobiological circuit is summarized
in Figure 1.
A growing body of work emphasizes the
cardioprotective properties of EPO, via
mechanisms unrelated to this cytokine’s
eponymous effect on the oxygen-carrying
capacity of blood. For example, in rats,
EPO blocks cardiac apoptosis after coro-
nary artery obstruction (Moon et al., 2003),
ascribed to an inhibition of the mitochon-
drial membrane permeability transition
pore (Juhaszova et al., 2004). Notably,
protection is evoked in cultured cardio-
myocytes and experimental animals
by an 11 amino acid peptide from thell 9, August 5, 2011 ª2011 Elsevier Inc. 95
Figure 1. The STAT3-EPO-CCL2 Pathway for Cardiac Blood Vessel Formation and Its
Dysregulation in Heart Failure
Cardiomyocytes’ expression of STAT3 is essential for local EPO production, which directs the differenti-
ation of Sca-1+ CPCs into vascular endothelium. Methoxy polyethylene glycol-epoetin beta, a long-lasting
EPO derivative, can bypass the requirement for endogenous EPO production, activate blood vessel
formation by Sca-1+ CPCs, improve cardiac pump function in the conditional knockout of STAT3, and
overcome doxorubicin-induced cardiotoxicity.
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2010). This peptide serves as one of
several means used to dissociate EPO’s
capacity for cytoprotection from erythro-
cyte production, and therefore may over-
come the hazard of thrombosis that can
occur in response to EPO therapy (Leist
et al., 2004). Acuteprotection fromcardiac
injury is likely mediated by the expression
of EPOR in cardiomyocytes and is contin-
gent on its forming a heterodimer with
CD131, a subunit for many cytokines
(Brines et al., 2008). In contrast to this
ostensibly direct block of cardiomyocyte
death, Hoch and colleagues have un-
masked a distinct, indirect protective
mechanism for EPO, by virtue of its ability
to rescue impaired CPC differentiation
into a vascular network.96 Cell Stem Cell 9, August 5, 2011 ª2011 ElWhile the present investigations have
been conducted in mouse models, the
observed downregulation of STAT3 and
EPO protein levels in failing human hearts
suggests that this pathway might operate
in a clinically relevant context as well.
Conceivably, this circuit is also disrupted
by other important anticancer drugs that
exhibit cardiotoxicity, like tyrosine kinase
inhibitors (Force and Kolaja, 2011). As
a cautionary note, the authors have not
yet proven that resident Sca-1+ cells are
the critical target for EPO in vivo (rather
than circulating progenitor cells, pre-
formed endothelium, cardiomyocytes, or
even epicardium) (Brade et al., 2011).
Impaired cardiac muscle creation by the
CPCs (Oh et al., 2003) would also be
consistent with the authors’ findings andsevier Inc.is a tantalizing alternative yet to be ad-
dressed. Despite these opportunities for
future refinement, it is always welcome
to see that an FDA-approved agent
exhibits additional candidate therapeutic
activity, especially, such as here, when
novel mechanistic insights are revealed.REFERENCES
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